[News] Durvalumab boosts progression-free survival in NSCLC

Durvalumab might significantly improve progression-free survival in patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) previously treated with chemoradiotherapy, according to interim results from a randomised phase 3 trial.

Source: The Lancet Oncology - November 23, 2017 Category: Cancer & Oncology Authors: Elizabeth Gourd Tags: News Source Type: research